A groundbreaking weight-loss medication has enabled a woman to lose more than three and a half stones within two years.
A once-daily GLP-1 tablet known as Foundayo, which has been informally referred to as the ‘Mounjaro pill’ on the internet, has generated significant attention in the field of obesity treatment after positive results from clinical trials.
Clinical trial participant Maggie Linton, a U.S. volunteer involved in a MedStar Health study examining the effects of Foundayo, mentioned that she started observing changes within a few weeks of beginning the treatment.
“It had a significant impact right away,” she remarked.
I could observe my weight, along with my cholesterol and all other factors, decreasing simultaneously.
Throughout the trial, she shed approximately 3.6 stone over two years, decreasing from 16.7 stone to roughly 13.2 stone.
She mentioned that side effects were generally mild, noting only temporary constipation at the beginning of the treatment.
In contrast to Mounjaro, an injectable medication that is commonly used, the oral treatment functions in a comparable manner by focusing on hormones that control hunger, enabling patients to experience a prolonged sense of fullness and decreasing their consumption of food.
The tablet is part of a new wave of GLP-1-based therapies, which have already revolutionized weight management with medications like Ozempic and Mounjaro, but have traditionally needed to be administered via injection.
“But I discovered how to eat more healthily, exercise a bit more, and that issue faded away,” she added.
Ms. Linton mentioned that lifestyle adjustments were also crucial to her achievements, such as walking, tai chi, and Pilates, which she attributes to assisting her in sustaining her progress.
Experts note that the attraction of oral GLP-1 medications stems from their ease of use in comparison to injections, with daily pills possibly increasing treatment availability if approved on a larger scale.
Nevertheless, specialists keep cautioning that these drugs may have adverse effects, such as vomiting, gastrointestinal problems, and, in uncommon instances, more severe consequences, while emphasizing that they work best when used alongside dietary and lifestyle modifications.
The contraceptive pill was created by the major drug company Eli Lilly following its approval for use in the United States.
The drug’s approval in the United States is anticipated to boost international attention, as obesity therapies increasingly move toward more convenient oral forms instead of injections.
In January, the oral form of the popular weight-loss medication Wegovy was introduced in the United States.
The Danish pharmaceutical company Novo Nordisk, its creator, had earlier informed the Daily Mail that they are aiming to introduce the pill in the UK, with a regulatory application expected in 2026.
“Concerning the UK, we are aiming to submit Wegovy in a pill form in 2026,” a representative from Novo Nordisk UK stated, noting they were unable to provide additional information on the schedule at this time.
The choice made by the United States was carried out by the Food and Drug Administration, after extensive clinical studies on the once-daily Wegovy tablet, which showed it to be equally effective as the injectable version.
The device includes 25mg of semaglutide – the same active component found in the injectable medication Wegovy and the diabetes treatment Ozempic.
Although Ozempic is approved for the treatment of type 2 diabetes and is frequently used in an unapproved manner for weight reduction, Wegovy was created and authorized exclusively for the management of obesity.
In studies with approximately 1,300 individuals, those who took the Wegovy tablet shed an average of 16.6 percent of their body weight within a little more than a year, as reported by Novo Nordisk.
jasdooit 
Leave a comment